Well 2016 is officially in the history books and what a wild ride it was. Do you think 2017 will be just as exciting? Well for the IPO markets investors are really hoping it will, and as of last week we got a small sign that it will at least be off to a good start. There have already been four companies that have filed to go public in 2017. Those companies also provide a good mix of industry, including a tech company, a coal miner, and two biotech's.
AppDynamics (NASDAQ: APPD) - according to their website they are an application performance monitoring provider. The company just filed on Tuesday and has indicated that they are looking to raise around $150 million. For 2017 it is expected that more tech companies come to the IPO markets as their initial investors will be looking for an exit.
Ramaco (NASDAQ: METC) is a newer coal mining company with sites in Wyoming, Virginia and West Virginia. The company will be looking for $100 million according to their filing but insiders have indicated that they will be shooting much more. According to their filing, it has 170 million tons in proved recoverable reserves, and expects to have initial commercial production in the first quarter. If successful it would be the first coal mining company to go public since June 2015, when Consol energy launched (NASDAQ: CNXC).
Jounce Therapeutics (NASDAQ: JNCE) is a biotech which is in the clinical stage of developing cancer immunotherapies. The company will be looking to raise $75 million according to their filing. Based out of Cambridge, MA the company began clinical trials for its lead product candidate JTX-2011 in August. In July, Jounce announced a collaboration with Celgene (NASDAQ: CELG) worth up to $2.5 billion, including $225 million paid up front with an additional $36 million equity investment.
ObsEva (NASDAQ: OBSV) is a biotech company that is based in Switzerland that is developing therapies for women's reproductive health and pregnancy,. The company will be looking to raise more than $86 million to continue to fund their four clinical stage products.